HOME > COMMENTARY
COMMENTARY
- COMMENTARY/Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
- Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
- COMMENTARY/Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
- COMMENTARY/National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
- Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
- Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
- Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
- COMMENTARY/Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
- COMMENTARY/Aiming at Further Growth beyond Global Recession
January 12, 2009
- COMMENTARY/Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
- COMMENTARY/Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
- Commentary/Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
- COMMENTARY/Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
- COMMENTARY/Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
- SURVEY/DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
- COMMENTARY/Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
- COMMENTARY/Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
- COMMENTARY/Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
- COMMENTARY/Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
- COMMENTARY/Reform of Ethical Drug Distribution Practices
September 1, 2008
ページ
The advance of cell therapy is one of the most exciting innovations in medical treatment in recent years. These drugs offer potential curative treatments for severe or previously fatal diseases. In this article, I will explain features and challenges in…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…